Brand launch and lifecycle strategy
Post-Marketing Safety Communication and Promotional Label Alignment
Misaligned safety labels and promotional materials create compliance and patient safety risks.
By Renata Solis-Vega
Thursday, November 5, 2026Independent reporting on pharmaceutical marketing: MLR and promotional review, modular content, HCP and patient engagement.
Brand launch and lifecycle strategy
Rare Disease Drug Launch Constraints Under Orphan Drug Regulations
Orphan drug sponsors must align regulatory choices with market-access strategy before launch.
Brand launch and lifecycle strategy
Loss of Exclusivity Brand Strategy and Authorized Generic Messaging
Successful post-patent strategy depends on tailored approaches, not uniform cost cuts.
Brand launch and lifecycle strategy
KOL Engagement Programs and Speaker Bureau Compliance Obligations
Pharma speaker programs face four overlapping legal regimes and sustained enforcement scrutiny.
Brand launch and lifecycle strategy
Competitive Response Content Strategy Within FDA Promotional Rules
FDA's tighter grip on competitive pharma ads now scrutinizes overall tone and presentation.
Brand launch and lifecycle strategy
Rare Disease Drug Launch Constraints Under Orphan Drug Regulations
Orphan drug sponsors must align regulatory choices with market-access strategy before launch.
Loss of Exclusivity Brand Strategy and Authorized Generic Messaging
Successful post-patent strategy depends on tailored approaches, not uniform cost cuts.
KOL Engagement Programs and Speaker Bureau Compliance Obligations
Pharma speaker programs face four overlapping legal regimes and sustained enforcement scrutiny.
Competitive Response Content Strategy Within FDA Promotional Rules
FDA's tighter grip on competitive pharma ads now scrutinizes overall tone and presentation.
Market access and payer communications
Health Care Economic Information Under FDAMA 114 Guidance
FDA finally clarified how drugmakers can share cost data with insurers and formulary committees.
Budget Impact Model Presentation Standards for Payer Audiences
ISPOR and ICER standards now jointly determine what budget impact analyses payers will accept.
Patient Assistance Program Communication Compliance for Brand Teams
Recent rulings narrow brand teams' legal defenses for patient assistance program involvement.
Medicaid Managed Care Plan Engagement Strategy for Drug Brands
Drug brands must navigate three hidden layers—MCO, PBM, and formulary—to reach Medicaid patients.
MLR and promotional review
Handling Unsolicited Requests for Off-Label Drug Information
Manufacturers must verify requests are unsolicited before sharing off-label drug information.
Social Media Promotional Content Under FDA Off-Label Oversight
The FDA is now enforcing drug-promotion rules on social media platforms it long ignored.
Veeva Vault PromoMats Configuration for MLR Cycle Management
Granular system setup, not slow reviewers, determines if MLR clears in days or weeks.
FDA Draft Guidance on Directional Risk Information in Promotional Labeling
Sixteen-year-old draft guidance now drives FDA's crackdown on drug marketing risk disclosures.
HCP and patient engagement
Digital Therapeutics and Prescription Drug Co-Promotion Compliance
Pharma-DTx deals multiply compliance complexity as regulatory gaps widen.
Congress and Medical Meeting Promotional Booth Compliance
Pharma booth panels face the same FDA promotional rules as ads, and enforcement is accelerating.
FDA Regulations on Patient Testimonials in Drug Advertising
Brands must treat paid patient testimonials as drug claims subject to full safety disclosure.
Patient Support Program Design for Adherence in Chronic Disease
Effective design and targeted support can close the gaps where patients abandon their medications.